Cargando…

From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real‐world setting

Melanoma currently lacks a reliable blood‐based biomarker of disease activity, although circulating tumor DNA (ctDNA) may fill this role. We investigated the clinical utility (i.e., impact on clinical outcomes and interpretation of radiographic data) of measuring ctDNA in patients with metastatic or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rowe, Steven P., Luber, Brandon, Makell, Monique, Brothers, Patricia, Santmyer, JoAnn, Schollenberger, Megan D., Quinn, Hannah, Edelstein, Daniel L., Jones, Frederick S., Bleich, Karen B., Sharfman, William H., Lipson, Evan J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165998/ https://www.ncbi.nlm.nih.gov/pubmed/30113761 http://dx.doi.org/10.1002/1878-0261.12373

Ejemplares similares

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
por: Lipson, Evan J., et al.
Publicado: (2017)

Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma
por: Rosner, Samuel, et al.
Publicado: (2020)

Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series
por: LoPiccolo, Jaclyn, et al.
Publicado: (2019)

Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting
por: Lipson, Evan J, et al.
Publicado: (2015)

Adjuvant radiotherapy and outcomes of presumed hemorrhagic melanoma brain metastases without malignant cells
por: Xia, Yuanxuan, et al.
Publicado: (2018)

Acute axillary lymphadenopathy detected shortly after COVID-19 vaccination found to be due to newly diagnosed metastatic melanoma
por: Gullotti, David M, et al.
Publicado: (2022)

Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis
por: Jain, Animesh, et al.
Publicado: (2017)

Utility of Serial Donor-derived Cell-free DNA Measurements for Detecting Allograft Rejection in a Kidney Transplant Recipient After PD-1 Checkpoint Inhibitor Administration
por: Lakhani, Laila, et al.
Publicado: (2021)

Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
por: Lipson, Evan J, et al.
Publicado: (2014)

Anti-RA33 antibodies are present in a subset of patients with immune checkpoint inhibitor-induced inflammatory arthritis
por: Cappelli, Laura C, et al.
Publicado: (2022)

A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain
por: Ruzevick, Jacob, et al.
Publicado: (2013)

A Case Report of Primary Recurrent Malignant Melanoma of the Urinary Bladder
por: Truong, Hong, et al.
Publicado: (2013)

Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation
por: Morales, Rita E, et al.
Publicado: (2015)

Melanoma metastatic to the hyoid bone
por: Ryan, John F., et al.
Publicado: (2020)

Circulating Tumor Cells in Melanoma Patients
por: Clawson, Gary A., et al.
Publicado: (2012)

Circulating Melanoma Cells: Scoping the Target
por: Joshi, Powrnima, et al.
Publicado: (2013)

Measurement of PD-L1 in melanoma: a quantitative antibody comparison
por: Sunshine, Joel C, et al.
Publicado: (2015)

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series
por: Moseley, Kendall F., et al.
Publicado: (2018)

Melanoma, Darwinian medicine and the inner world
por: Krone, B., et al.
Publicado: (2010)

The Circulating Transcriptome as a Source of Biomarkers for Melanoma
por: Solé, Carla, et al.
Publicado: (2019)

Circulating Tumour DNA in Melanoma—Clinic Ready?
por: Tivey, Ann, et al.
Publicado: (2022)

Current Trends in Circulating Biomarkers for Melanoma Detection
por: Huang, Nancy, et al.
Publicado: (2022)

Re-orienting the immune system: Durable tumor regression and successful re-induction therapy using anti-PD1 antibodies
por: Lipson, Evan J.
Publicado: (2013)

Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma
por: Beasley, Aaron, et al.
Publicado: (2018)

Fabricated: the new world of 3D printing : the promise and peril of a machine that can make (almost) anything
por: Lipson, Hod, et al.
Publicado: (2013)

Clinical correlates of circulating cell-free DNA tumor fraction
por: Bredno, Joerg, et al.
Publicado: (2021)

Detection of circulating melanoma cells in choroidal melanocytic lesions
por: Bande, Manuel F., et al.
Publicado: (2015)

Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma
por: Joshi, Powrnima, et al.
Publicado: (2014)

Circulating Melanoma-Derived Extracellular Vesicles: Impact on Melanoma Diagnosis, Progression Monitoring, and Treatment Response
por: Bollard, Stephanie M., et al.
Publicado: (2020)

Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios
por: Khaddour, Karam, et al.
Publicado: (2022)

Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma Patients
por: Gorges, Katharina, et al.
Publicado: (2019)

Drug-Induced Melanoma: Irbesartan Induced Cutaneous Melanoma! First Description in the World Literature!
por: Tchernev, Georgi, et al.
Publicado: (2019)

Melanoma: Does It Present Differently in Darker Skin Tones?
por: Thompson, Brandon, et al.
Publicado: (2023)

Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors
por: Epstein, Robert S., et al.
Publicado: (2020)

Pre-Diagnostic Circulating Vitamin D and Risk of Melanoma in Men
por: Major, Jacqueline M., et al.
Publicado: (2012)

Circulating microRNAs as Candidate Biomarkers for the Surveillance of Melanoma Patients
por: Behrmann, Iris, et al.
Publicado: (2015)

Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment
por: Gray, Elin S, et al.
Publicado: (2015)

Methylated circulating tumor DNA as a biomarker in cutaneous melanoma
por: Diefenbach, Russell J, et al.
Publicado: (2020)

Single-Cell Identification of Melanoma Biomarkers in Circulating Tumor Cells
por: Fankhauser, Reilly, et al.
Publicado: (2022)

Detection of metastases using circulating tumour DNA in uveal melanoma
por: Beasley, Aaron B., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fj30pla7a6alkrfad5314k305j